[Skip to Content]
[Skip to Content Landing]
Views 244
Citations 0
Correction
January 2017

Incorrect Numbers at Risk in Figure

Author Affiliations
 

Copyright 2016 American Medical Association. All Rights Reserved.

JAMA Otolaryngol Head Neck Surg. 2017;143(1):97. doi:10.1001/jamaoto.2016.4352

In the Original Investigation titled “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial,” published in the September issue of JAMA Otolaryngology–Head & Neck Surgery,1 incorrect values for the numbers of patients at risk appeared in Figure 2A. At day 30, the numbers of patients at risk should be 34 for CRT (cetuximab plus radiotherapy) and 25 for radiotherapy alone (not 3 and 2). This article was corrected online.

References
1.
Bonner  J, Giralt  J, Harari  P,  et al.  Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: a secondary analysis of a randomized clinical trial.  JAMA Otolaryngol Head Neck Surg. 2016;142(9):842-849.PubMedGoogle ScholarCrossref
×